Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s LymphomaZhitao Ying, Jun Zhu|Molecular Therapy — Oncolytics|2019Cited by 166
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophagesLingyan Ping, Jun Zhu|Oncotarget|2017Cited by 86
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Jun Zhu, Haiyan Yang et al.|The Lancet Oncology|2023Cited by 55
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphomaHui Yu, Jun Zhu|Molecular Therapy — Oncolytics|2021Cited by 46
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphomaYalu Liu, Jun Zhu|Cancer Cell International|2019Cited by 38